Kailera

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Kailera Therapeutics shares surged 62.5% in its Nasdaq IPO, raising $625 million amid intense competition in the weight-loss drug market dominated by GLP-1 therapies.